JP2022507474A5 - - Google Patents

Info

Publication number
JP2022507474A5
JP2022507474A5 JP2021526441A JP2021526441A JP2022507474A5 JP 2022507474 A5 JP2022507474 A5 JP 2022507474A5 JP 2021526441 A JP2021526441 A JP 2021526441A JP 2021526441 A JP2021526441 A JP 2021526441A JP 2022507474 A5 JP2022507474 A5 JP 2022507474A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutical composition
cancer
group
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021526441A
Other languages
English (en)
Japanese (ja)
Other versions
JP7461350B2 (ja
JP2022507474A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/061657 external-priority patent/WO2020102646A2/en
Publication of JP2022507474A publication Critical patent/JP2022507474A/ja
Publication of JP2022507474A5 publication Critical patent/JP2022507474A5/ja
Application granted granted Critical
Publication of JP7461350B2 publication Critical patent/JP7461350B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021526441A 2018-11-16 2019-11-15 Arg1及び/又はarg2の阻害剤 Active JP7461350B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862768284P 2018-11-16 2018-11-16
US62/768,284 2018-11-16
PCT/US2019/061657 WO2020102646A2 (en) 2018-11-16 2019-11-15 Inhibitors of arg1 and/or arg2

Publications (3)

Publication Number Publication Date
JP2022507474A JP2022507474A (ja) 2022-01-18
JP2022507474A5 true JP2022507474A5 (https=) 2022-11-24
JP7461350B2 JP7461350B2 (ja) 2024-04-03

Family

ID=70731928

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021526441A Active JP7461350B2 (ja) 2018-11-16 2019-11-15 Arg1及び/又はarg2の阻害剤

Country Status (12)

Country Link
US (1) US12226425B2 (https=)
EP (1) EP3880685B1 (https=)
JP (1) JP7461350B2 (https=)
KR (1) KR102718333B1 (https=)
CN (1) CN113382998A (https=)
AR (1) AR117102A1 (https=)
AU (1) AU2019379808C1 (https=)
CA (1) CA3120196A1 (https=)
ES (1) ES3034676T3 (https=)
TW (1) TWI828800B (https=)
UY (1) UY38476A (https=)
WO (1) WO2020102646A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119118872A (zh) 2020-03-19 2024-12-13 艾库斯生物科学有限公司 作为HIF-2α抑制剂的四氢化萘和四氢喹啉化合物
MX2022015157A (es) 2020-06-02 2023-01-16 Arcus Biosciences Inc Anticuerpos para tigit.
KR20230026312A (ko) 2020-06-17 2023-02-24 아르커스 바이오사이언시즈 인코포레이티드 Cd73 억제제의 결정형 및 이의 용도
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
WO2022246179A1 (en) 2021-05-21 2022-11-24 Arcus Biosciences, Inc. Axl inhibitor compounds
EP4341261A1 (en) 2021-05-21 2024-03-27 Arcus Biosciences, Inc. Axl compounds
WO2023077046A1 (en) 2021-10-29 2023-05-04 Arcus Biosciences, Inc. Inhibitors of hif-2alpha and methods of use thereof
AU2023264591A1 (en) 2022-05-02 2024-11-07 Arcus Biosciences, Inc. Anti-tigit antibodies and uses of the same
WO2024015251A1 (en) 2022-07-15 2024-01-18 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
EP4558501A1 (en) 2022-07-20 2025-05-28 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
CN119768155A (zh) 2022-09-14 2025-04-04 艾库斯生物科学有限公司 依曲地南的分散体
EP4602041A1 (en) 2022-10-14 2025-08-20 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
US20240180947A1 (en) 2022-10-20 2024-06-06 Arcus Biosciences, Inc. Lyophilized formulations of cd73 compounds
WO2024233360A1 (en) 2023-05-05 2024-11-14 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
EP4720055A1 (en) 2023-05-25 2026-04-08 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
US20260116868A1 (en) 2023-10-06 2026-04-30 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2025193759A1 (en) 2024-03-12 2025-09-18 Gilead Sciences, Inc. Solid forms of an azolopyrimidine compound

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952294A (en) 1996-07-31 1999-09-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptidyl prodrugs and methods of making and using the same
AU9797998A (en) 1997-10-10 1999-05-03 Trustees Of The University Of Pennsylvania, The Compositions and methods for inhibiting arginase activity
EP1399467A4 (en) 2001-05-09 2004-09-15 Newbiotics Inc PRODRUGS ACTIVATED BY PEPTIDDEFORMYLASE
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ox40l抗體
PT2343320T (pt) 2005-03-25 2018-01-23 Gitr Inc Anticorpos anti-gitr e as suas utilizações
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
EP2249853A4 (en) 2008-01-30 2012-12-26 Univ Indiana Res & Tech Corp ESTER BASED PEPTIDE PRODRUGS
EP2730579A1 (en) 2008-06-17 2014-05-14 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
RU2488390C2 (ru) 2008-12-29 2013-07-27 Тартуский Университет Ингибиторы аргиназы для лечения депрессии
LT2389352T (lt) 2009-01-26 2019-06-10 The Trustees Of The University Of Pennsylvania Arginazės inhibitoriai ir naudojimo būdai
KR101790802B1 (ko) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-gitr 항체
WO2011038061A2 (en) 2009-09-25 2011-03-31 Alcon Research, Ltd. Novel npr-b agonists
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
EP2542256B1 (en) 2010-03-04 2019-05-22 MacroGenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトcsf−1rに対する抗体及びその使用
SG10201503168VA (en) 2010-04-22 2015-06-29 Mars Inc Inhibitors of arginase and their therapeutic applications
HRP20190047T1 (hr) 2010-05-04 2019-02-22 Five Prime Therapeutics, Inc. Protutijela koja se vežu na csf1r
MX337040B (es) 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
HRP20160305T1 (hr) 2010-10-26 2016-07-01 Mars, Incorporated Borati kao inhibitori arginaze
CA2824599C (en) 2010-12-31 2020-03-10 Astrazeneca Uk Limited Arginase inhibitors and methods of use thereof
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン,エルエルシー B7−h1およびpd−1に結合する抗体およびその他の分子
WO2013059437A1 (en) 2011-10-19 2013-04-25 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-pd-l1 항체 및 그의 용도
RU2658603C2 (ru) 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
KR20140127855A (ko) 2012-02-06 2014-11-04 제넨테크, 인크. Csf1r 억제제를 사용하는 조성물 및 방법
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
CN104540836B (zh) * 2012-04-18 2016-11-09 马尔斯公司 作为精氨酸酶抑制剂的环约束类似物
RU2670743C9 (ru) 2012-05-11 2018-12-19 Файв Прайм Терапьютикс, Инк. Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
WO2014007831A1 (en) 2012-07-06 2014-01-09 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
AU2014278172B2 (en) 2013-06-12 2018-08-09 Mycovia Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2015160664A1 (en) 2014-04-15 2015-10-22 Dow Agrosciences Llc Metalloenzyme inhibitor compounds as fungicides
CL2014002403A1 (es) 2014-09-11 2015-01-09 Univ Pontificia Catolica Chile Metodo para la preparacion enantioselectiva y purificacion del acido 2(s)-amino-6-boronohexanoico (abh) a partir de la disolucion de bpb-ni-gly en tetrahidrofurano, neutralizacion y posterior extraccion con diclorometano, disolucion en un alcohol c1-c5, enfriamiento para lograr la precipitacion de bpb, obtencion de abh y su posterior purificacion.
WO2016100555A1 (en) 2014-12-18 2016-06-23 Inception 4, Inc. Boronic acid derivatives and uses thereof
PL410665A1 (pl) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
US10143699B2 (en) * 2015-06-23 2018-12-04 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
SG11201802961PA (en) 2015-10-30 2018-05-30 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
EP3490542A4 (en) * 2016-07-26 2020-07-08 Flagship Pioneering Innovations V, Inc. NEUROMODULATION COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATION OF AN ANTI-CANCER RESPONSE
JP2020502259A (ja) * 2016-11-08 2020-01-23 カリセラ バイオサイエンシズ,インコーポレイテッド アルギナーゼ阻害剤併用療法
AU2019229978B2 (en) 2018-03-05 2024-05-30 Arcus Biosciences, Inc. Arginase inhibitors
WO2019245890A1 (en) 2018-06-20 2019-12-26 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use

Similar Documents

Publication Publication Date Title
JP2022507474A5 (https=)
JP2021516237A5 (https=)
JP2023518286A5 (https=)
JP2022535120A5 (https=)
JP2019529500A5 (https=)
IL295569A (en) Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
JP2019535720A5 (https=)
JP2021531314A5 (https=)
JP2016534148A5 (https=)
JP2020519664A5 (https=)
JP2021515775A5 (https=)
RU2014110623A (ru) Пирролопиразиновые ингибиторы киназы
JP2016519072A5 (https=)
RU2016137181A (ru) Противофиброзные пиридиноны
JP2024521706A5 (https=)
AR102094A1 (es) Inhibidores de proteínas kras con una mutación g12c
JP2016500661A5 (https=)
JP2016520131A5 (https=)
JP2010539110A5 (https=)
KR20190041471A (ko) 케모카인 수용체 조절제 및 이의 용도
JP2017538677A5 (https=)
JP2016534059A5 (https=)
JP2018528261A5 (https=)
CA2734415A1 (en) Picolinamide derivatives as kinase inhibitors
JP2010538091A5 (https=)